Septerna (NASDAQ:SEPN) Posts Earnings Results, Beats Expectations By $0.32 EPS

Septerna (NASDAQ:SEPN) released its quarterly earnings data on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.32, FiscalAI reports. Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%.

Septerna Trading Down 1.3%

SEPN opened at $23.57 on Tuesday. The stock has a 50-day moving average price of $25.25 and a 200-day moving average price of $25.42. Septerna has a 12-month low of $6.44 and a 12-month high of $32.63. The stock has a market capitalization of $1.06 billion, a P/E ratio of -21.23 and a beta of 2.21.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SEPN. JPMorgan Chase & Co. boosted their price objective on Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Truist Financial upped their target price on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Stifel Nicolaus started coverage on Septerna in a research note on Friday, May 1st. They issued a “buy” rating and a $43.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Tuesday, April 21st. Finally, Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Septerna has an average rating of “Moderate Buy” and an average price target of $43.13.

Insider Activity

In related news, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at $22,283.30. This represents a 98.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total value of $97,360.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This represents a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 78,453 shares of company stock valued at $2,192,969 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Septerna

Institutional investors have recently bought and sold shares of the stock. Group One Trading LLC boosted its holdings in Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new stake in Septerna during the 4th quarter valued at about $35,000. Russell Investments Group Ltd. purchased a new stake in Septerna during the 3rd quarter valued at about $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Septerna during the 4th quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Septerna during the 4th quarter valued at about $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.